News | June 02, 2011

Resynchronization Therapy Using Nicom Hemodynamic Monitoring Improves Heart Failure Outcomes

June 3, 2011 - In a two studies published recently in Heart Rhythm Society annual meeting, Investigators from the department of cardiology in Addenbrooke's Hospital in Cambridge, U.K., found that Cheetah Medical's Nicom system is an effective and practical method for optimizing the function of cardiac resynchronization therapy (CRT) pacemakers.

The investigators found that heart failure patients whose pacemaker parameter settings were adjusted to maximize cardiac output measured noninvasively by Nicom had better outcomes than patients who did not receive such an optimization procedure. Another finding of the studies was that patients who demonstrated a significant increase in cardiac output measured by Nicom (so called "acute responders") experienced better two-year survival with CRT treatment than patients who did not exhibit such a response.

CRT pacemakers are standard treatment for a large portion of heart failure patients and the number of CRT device implantations has grown rapidly over the past decade since they have been shown to improve patient symptoms and prognosis. However, as many as 40 percent of CRT patients do not improve clinically; they are considered non-responders. Among the proposed reasons for such a high rate of non-responsiveness is lack of appropriate adjustment of key parameters of the CRT device to effectively treat the pathology of individual patients.
In the two studies, the investigators demonstrate that by measuring patients' cardiac output with Nicom in a simple bed-side procedure it is possible to fine-tune pacemaker settings in order to maximize cardiac function. This led to a significant improvement in patients' clinical response, manifesting by heart failure severity score, improved quality of life, improvement in cardiac architecture and heart strength. Those results were significantly superior in comparison to the group of patients who did not undergo the optimization procedure with Nicom. Another interesting finding was that patients who showed significant response to the Nicom-guided optimization procedure experienced better long-term survival. This finding has potentially profound implications on clinical decisions physicians may make immediately after or even during the CRT implantation procedure.

Lead investigator Dr. Fakhar Khan says, "The two recent studies suggest an important potential role of non invasive acute hemodynamic monitoring in patients with advanced heart failure. The current work suggests that hemodynamically driven optimization is feasible using Nicom and in this small study, outcomes appear to be better. The results do have to be tested in larger randomized studies but offer the promise of a simple widely accessible method of CRT device optimization. The relationship of acute changes in Nicom to longer term survival suggests that Nicom can help prognosticate in CRT recipients and holds the promise for an early endpoint to guide treatment, not only through device optimization but also potentially the implant procedure itself."

Over the last decades CRT became a valuable tool in the armamentarium of heart failure specialists for their patients. With an increasing number of CRT device implantations, clinicians began looking for ways to improve clinical results and overall quality of life. Custom tailoring the device settings, a procedure referred to as CRT optimization, has long been suggested as one way to achieve those goals. Nicom enables, for the first time, a simple user friendly, non-invasive, bedside solution for CRT optimization and can provide clinicians insight as to the patients' long-term results. These studies demonstrate that there is significant clinical benefit in Nicom-based optimization of CRT devices.

Cheetah Medical's Nicom non-invasive cardiac output and hemodynamic monitoring system uses the company's proprietary Bioreactance technology to deliver continuous, accurate, non-invasive cardiac output and other vital hemodynamic parameters, useful for fluid management and drug titration. Nicom is the only non-invasive hemodynamic monitor whose predicate for FDA clearance was the gold standard Continuous Cardiac Output Swan-Ganz catheter (pulmonary artery catheter).

For more information:

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init